Rational use of cetuximab in the treatment of advanced non-small cell lung cancer

OncoTargets and Therapy

Volumn 2, Issue , 2009, Pages 251-260

  Aggarwal, Charu ^a   Borghaei, Hossein ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Cetuximab; Lung cancer; Monoclonal antibody

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PANITUMUMAB; PEMETREXED; STEROID;

ACNE; ADJUVANT THERAPY; ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CHILL; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; HYPERSENSITIVITY REACTION; HYPOMAGNESEMIA; LOADING DRUG DOSE; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PROTEIN FUNCTION; RECEPTOR AFFINITY; REVIEW; SKIN TOXICITY; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; UNITED STATES;

EID: 77953371486     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Jemal A, Siegel R, Ward E, et al; Cancer statistics, CA Cancer J Clin. 2008;58:71-96.
2. Jemal A, Thun MJ, Ries LA, et al; Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100:1672-1694.
3. Goldstraw P, Crowley J, Chansky K, et al; The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706-714. (Pubitemid 47357522)
4. Greene F, Page D, Fleming I. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
5. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351-360. (Pubitemid 38101630)
6. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719-727. (Pubitemid 44283661)
7. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst. 2003;95:1453-1461. (Pubitemid 37279330)
8. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26:173-182. (Pubitemid 38759943)
9. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589-2597. (Pubitemid 41007845)
10. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26:5043-5051.
11. West H, Albain KS. Current standards and ongoing controversies in the management of locally advanced non-small cell lung cancer. Semin Oncol. 2005;32:284-292. (Pubitemid 40834485)
12. Eagan RT, Frytak S, Richardson RL, et al. A randomized comparative trial of sequential versus alternating cyclophosphamide, doxorubicin, and cisplatin and mitomycin, lomustine, and methotrexate in metastatic non-small-cell lung cancer. J Clin Oncol. 1988;6:5-8. (Pubitemid 18039984)
13. Cartei G, Cartei F, Cantone A, et al. Cisplatin-cyclophosphamide- mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst. 1993;85:794-800. (Pubitemid 23150310)
14. Mattson K, Maasilta P, Tammilehto L, et al. Trimetrexate and cyclophosphamide for metastatic inoperable nonsmall cell lung cancer. Semin Oncol. 1988;15:32-37. (Pubitemid 18137169)
15. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst. 1999;91:66-72.
16. Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer. 2000;83:447-453.
17. Ranson MR, White S, Thatcher N. Management of elderly patients with lung cancer. Curr Oncol Rep. 2000;2:90-95.
18. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000;18:122-130. (Pubitemid 30036345)
19. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998;16:2459-2465. (Pubitemid 28309041)
20. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non - small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210-3218. (Pubitemid 32591438)
21. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20:4285-4291. (Pubitemid 35266288)
22. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98. (Pubitemid 34438899)
23. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550. (Pubitemid 44917502)
24. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: Avail. J Clin Oncol. 2009;27:1227-1234.
25. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
26. Lustberg MB, Edelman MJ. Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr Treat Options Oncol. 2007;8:38-46.
27. Socinski MA, Stinchcombe TE. Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies. J Clin Oncol. 2007;25:5155-5157.
28. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
29. Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck. 2003;25:67-73. (Pubitemid 36005333)
30. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002;20:1S-13S. (Pubitemid 35051707)
31. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7:505-516. (Pubitemid 44036456)
32. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341-354. (Pubitemid 40637826)
33. Ferraro B, Bepler G, Sharma S, et al. EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol. 2005;23:1921-1926. (Pubitemid 46211370)
34. Haura EB, Zheng Z, Song L, et al. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res. 2005;11:8288-8294. (Pubitemid 41746939)
35. Lo HW, Hsu SC, Ali-Seyed M, et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell. 2005;7:575-589. (Pubitemid 40799250)
36. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132. (Pubitemid 41058344)
37. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-144. (Pubitemid 41058345)
38. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892-5899. (Pubitemid 46300205)
39. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25:1545-1552. (Pubitemid 46733081)
40. Baselga J: New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol 2000;18:54S-59S.
41. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995;1:1311-1318.
42. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer. 2001;37 Suppl 4:S16-S22. (Pubitemid 32938125)
43. Baselga J. Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol. 2001;19:S41-S44. (Pubitemid 32880078)
44. Baselga J. A review of EGFR targeted therapy. Clin Adv Hematol Oncol. 2003;1:218-219.
45. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000;18:904-914. (Pubitemid 30106623)
46. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:3234-3243. (Pubitemid 32591441)
47. Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7:301-311. (Pubitemid 40544648)
48. Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer. 2006;107:1207-1218. (Pubitemid 44452768)
49. Sigismund S, Argenzio E, Tosoni D, et al. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell. 2008;15:209-219.
50. Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol. 2004;44:195-217. (Pubitemid 38263839)
51. Fan Z, Shang BY, Lu Y, et al. Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res. 1997;3:1943-1948. (Pubitemid 27505119)
52. Peng D, Fan Z, Lu Y, et al. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 1996;56:3666-3669. (Pubitemid 26272010)
53. Wu X, Rubin M, Fan Z, et al. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene. 1996;12:1397-1403. (Pubitemid 26135156)
54. Zandi R, Larsen AB, Andersen P, et al. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal. 2007;19:2013-2023. (Pubitemid 47353811)
55. Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 2007;13:1552-1561. (Pubitemid 46450447)
56. Fan Z, Baselga J, Masui H, et al. Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies pluscis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993;53:4637-4642. (Pubitemid 23304392)
57. Hoffmann T, Hafner D, Ballo H, et al. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res. 1997;17:4419-4425. (Pubitemid 28081723)
58. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58:2825-2831. (Pubitemid 28311914)
59. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res. 2000;6:4874-4884. (Pubitemid 32110432)
60. Blagosklonny MV, Schulte T, Nguyen P, et al. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res. 1996;56:1851-1854. (Pubitemid 26118221)
61. Garcia R, Franklin RA, McCubrey JA. EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle. 2006;5:2820-2826. (Pubitemid 44901745)
62. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008;105:2070-2075.
63. Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 2006;10:25-38.
64. Rothenberg SM, Engelman JA, Le S, et al. Modeling oncogene addiction using RNA interference. Proc Natl Acad Sci U S A. 2008;105:12480-12484.
65. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039-1043. (Pubitemid 46799492)
66. Morgillo F, Kim WY, Kim ES, et al. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res. 2007;13:2795-2803. (Pubitemid 46788049)
67. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
68. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.
69. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992-3995.
70. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:e17. (Pubitemid 40412734)
71. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373:1525-1531.
72. O'Byrne K, Bondarenko I, Barrios C. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study. J Clin Oncol, 2009 ASCO Annual Meeting Proceedings. J Clin Oncol. 2009;27:15s, (suppl; abstr 8007).
73. Cappuzzo F, Ligorio C, Toschi L, et al. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol. 2007;2:423-429. (Pubitemid 47181697)
74. Hirsch FR, Varella-Garcia M, Cappuzzo F, et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2007;18:752-760. (Pubitemid 46523281)
75. Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008;26:3351-3357.
76. Cerny T, Barnes DM, Hasleton P, et al. Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer. 1986;54:265-269. (Pubitemid 16076118)
77. Thienelt CD, Bunn PA Jr, Hanna N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005;23:8786-8793. (Pubitemid 46211524)
78. Robert F, Blumenschein G, Herbst RS, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:9089-9096. (Pubitemid 46264008)
79. Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol. 2007;25:5777-5784.
80. Spigel D, Greco F, Burris H. Docetaxel, gemcitabine, and cetuximab in untreated advanced non-small cell lung cancer: P3-144. 12th World Conference on Lung Cancer; 2007 September 2-6; J Thorac Oncol, Seoul, Korea: 2007;2(8) Suppl 4:S740-S741.
81. Belani CP, Schreeder MT, Steis RG, et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer. 2008;113:2512-2517.
82. Borghaei H, Langer CJ, Millenson M, et al. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol. 2008;3:1286-1292.
83. Saleh M, Socinski M, Trent D. Randomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25(18S) June 20 Suppl:Abstract 7586.
84. Herbst R, Chansky K, Kelly K. A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): Final report of SWOG 0342. ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25(18S) June 20 Suppl: Abstract 7545.
85. Bradford D, Socinski M, LaRocca R. Phase II trial of carboplatin plus cetuximab for the treatment of stage IIIB/IV non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25(18S) June 20 Suppl:Abstract 18005.
86. Lilenbaum R, Wang X, Gu L. Phase II randomized trial of docetaxel plus cetuximab or bortezomib in patients with advanced NSCLC and performance status (PS) 2-CALGB 30402. ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25(18S) June 20 Suppl:Abstract 7595.
87. Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol. 2008;19:362-369. (Pubitemid 351201721)
88. Pirker R, Szczesna A, von Pawel J. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2008;26:(May 20 Suppl):Abstract 3.
89. Lynch T, Taral P, Luke D. A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC): B3-03. J Thorac Oncol. 2007;2(8) Suppl 4:S340-S341.
90. Hanna N, Lilenbaum R, Ansari R, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006; 24:5253-5258. (Pubitemid 46631370)
91. Jalal S, Waterhouse D, Edelman M. Pemetrexed plus cetuximab in patients (pts) with recurrent non-small cell lung cancer (NSCLC): A phase I-IIa dose-ranging study from the Hoosier Oncology Group. ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25(18S) June 20 Suppl:Abstract 7698.
92. Kim ES, Mauer AM, William WN Jr, et al. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall-cell lung cancer. Cancer. 2009.
93. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578. (Pubitemid 43209104)
94. Hughes S, Liong J, Miah A. Safety study of induction chemotherapy and synchronous radiotherapy (RT) and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH (Cohort I). ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25(18S) June 20 Suppl: Abstract 18032.
95. Blumenschein G, Paulus R, Curran W. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial. J Clin Oncol. 2008;26:(May 20 Suppl):Abstract 7516.
96. Govindan R, Bogart J, Wang X. A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407-Early evaluation of feasibility and toxicity. J Clin Oncol. 2008;26:(May 20 Suppl):Abstract 7518.
97. Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf. 2007;6:175-182. (Pubitemid 46380811)
98. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol. 2005;23:5235-5246. (Pubitemid 46224035)
99. Alexandrescu DT, Vaillant JG, Dasanu CA. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol. 2007;32:71-74.
100. Chou LS, Garey J, Oishi K, et al. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors. Clin Lung Cancer. 2006;8 Suppl 1:S15-S22.
101. Deslandres M, Sibaud V, Chevreau C, et al. Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors. Ann Dermatol Venereol Spec. 2008;1:16-24. (Pubitemid 351620943)
102. Rhee J, Oishi K, Garey J, et al. Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents. Clin Colorectal Cancer. 2005;5 Suppl 2:S101-S106.
103. Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25:5390-5396. (Pubitemid 350232214)
104. Thomas M: Cetuximab: adverse event profile and recommendations for toxicity management. Clin J Oncol Nurs. 2005;9:332-338.
105. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358:1109-11017.
106. O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 2007;25:3644-3648. (Pubitemid 47372602)
107. Groenestege WM, Thebault S, van der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest. 2007;117:2260-2267. (Pubitemid 47219571)
108. Wagner CA. Disorders of renal magnesium handling explain renal magnesium transport. J Nephrol. 2007;20:507-510.
109. NCI: Cetuximab in Lung Cancer | Open Studies. http://clinicaltrials.gov/. Accessed March 01, 2009.